Final Clinical Study Report Sample Clauses
The Final Clinical Study Report clause outlines the requirements and procedures for preparing and delivering the comprehensive report that summarizes the results and findings of a clinical study. Typically, this clause specifies the timeline for submission, the format and content standards the report must meet, and the responsibilities of each party involved in its preparation and review. For example, it may require the sponsor to provide the report within a set number of days after study completion and to include all relevant data analyses and interpretations. The core function of this clause is to ensure that all parties receive a complete and standardized account of the study outcomes, facilitating regulatory compliance and informed decision-making.
POPULAR SAMPLE Copied 1 times
Final Clinical Study Report. A document prepared by the clinical trial sponsor that is submitted to Regulatory Authorities at the conclusion of a clinical trial. The document summarizes the safety and efficacy findings for the Study Drug as determined by the subject clinical study.
Final Clinical Study Report. Sponsor shall provide Company with a final submission copy of the final clinical Study Report no later than one (1) calendar year after Study completion. The report shall include all AEs generated by the Study, irrespective of whether the AEs are serious or non-serious, and a causality assessment for each AE, regardless of whether the AE is related to the IMP.
Final Clinical Study Report. Institution shall provide Amgen with a final submission copy of the Final Clinical Study Report for the Study immediately upon […***…]. The report shall include, among other things, all AEs generated by the Study, irrespective of whether the AEs are serious or non-serious, and without regard to their causal relationship either to the Study Protocol or the Study Drug.
Final Clinical Study Report. Apellis will use Commercially Reasonable Efforts to prepare the final CSRs for the Trial. The final CSRs will be prepared by Apellis in material compliance with Applicable Laws, including ICH E3 guidelines, to ensure that the final CSRs meet, in all material respects, applicable standards to enable submission of applications for Regulatory Approval of the Product to FDA and EMA. The final CSRs will be promptly provided to the JSC.
Final Clinical Study Report. Following completion of an Ongoing Nanobiotix-Conducted Study or New Nanobiotix-Conducted Study, Nanobiotix will prepare and provide to ▇▇▇▇▇▇▇ for review and comment a draft of the final clinical study report and a complete data set for such study. Nanobiotix will incorporate any comments provided by ▇▇▇▇▇▇▇. Promptly following completion of the final clinical study report, Nanobiotix will provide such report and the complete data set to ▇▇▇▇▇▇▇.